Desktop Health Adds PhonoGraft Biofabrication Platform to Growing Technology Portfolio

Promising New 3D Printed Programmable and Biodegradable Graft Aims to Support Body’s Natural Healing and Regeneration Process

Desktop Health today announced the addition of the PhonoGraft platform to its growing technology portfolio. The PhonoGraft technology is being studied for possible use in an implantable device for repairing damaged eardrums, with a programmable biodegradable 3D printed graft that has the potential to be minimally invasive and offers patients decreased procedure times as well as improved healing and hearing outcomes. This biofabrication technology may also offer a promising pathway for soft tissue regeneration for a wide range of healthcare applications. (Photo: Business Wire)

NEWPORT BEACH, Calif.--()--Desktop Health, a healthcare business within Desktop Metal, Inc. (NYSE: DM) committed to developing 3D printing and biofabrication solutions for personalized medicine, today announced an acquisition that adds the PhonoGraft™ platform to its technology portfolio, with potential to support the body’s functional and morphological regeneration of the tympanic membrane. This biofabrication technology may also offer a promising pathway for soft tissue regeneration for a wide range of healthcare applications.

The PhonoGraft technology was initially developed by researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University, Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS), and Mass Eye and Ear in Boston (Mass Eye and Ear is a member of Mass General Brigham). Harvard’s Office of Technology Development has granted Desktop Metal an exclusive license to commercialize the platform.

“We believe that this platform may one day offer a groundbreaking solution to the millions of patients impacted by tympanic membrane perforation (TMP),” said Michael Jafar, President and CEO of Desktop Health. “PhonoGraft material technology, coupled with our leading biofabrication capabilities, has tremendous potential across a wide range of healthcare applications in soft tissue – from cardiovascular and neuronal grafts to plastic surgery. Today’s announcement marks the beginning of our journey to advance personalized medicine.”

The PhonoGraft technology is being studied for possible use in an implantable device for repairing damaged eardrums, with a programmable biodegradable 3D printed graft that has the potential to be minimally invasive and offer patients decreased procedure times and improved healing and hearing outcomes.

“I’m delighted for the members of my lab at Harvard and our collaborators at Mass Eye and Ear who jointly developed this innovative technology, and who successfully applied their entrepreneurial drive to demonstrate its potential. In addition to TMP relief, this advanced graft technology could pave the way for a multitude of healthcare products in the fields of cardiac, vascular, and plastic surgery,” said Jennifer Lewis, ScD, who is a Core Faculty member at the Wyss Institute, a Hansjorg Wyss Professor of Biologically Inspired Engineering, and a Jianming Yu Professor of Arts and Sciences at Harvard SEAS.

Pioneering Breakthrough in 3D Printing Biomimicry
The concept for the PhonoGraft device arose after the 2013 Boston Marathon bombings, when many individuals sustained eardrum perforations due to the blast injury. Nicole Black, PhD, then a doctoral student in Lewis’ Harvard lab, recognized an opportunity to explore ways in which 3D printing might be used to improve outcomes following eardrum reconstruction. Lewis and her research group, in collaboration with ear surgeons Dr. Aaron Remenschneider and Dr. Elliott Kozin from Mass Eye and Ear, assembled a multidisciplinary team of material scientists and otolaryngologists.

“One of the most prevalent injuries of the Boston Marathon bombing was perforated eardrums,” said Dr. Remenschneider. “This is also common in military personnel after blast injury and in children and adults with ear infections. Surgical repair of the eardrum is unfortunately necessary for many patients to restore hearing and create a ‘safe’ ear.”

Six years of research and development, with an infusion of focused translational funding from the Wyss Institute, led to the creation and preclinical de-risking of the PhonoGraft material and device platform. Black became an entrepreneurial champion for the technology; she and several colleagues founded a startup, Beacon Bio, to advance the technology into commercial development. Beacon Bio has now been acquired by Desktop Metal.

The PhonoGraft device is a biomimetic graft that has the potential to enable high-quality and long-lasting eardrum reconstruction. Partnering with surgeons to develop the technology and understand critical features, such as the acoustic and mechanical properties of the graft material, has been important in its development, Black said.

“This device, which is manufactured from a biodegradable elastomer in the form of customizable biomimetic circular and radial scaffolds, is intended to function like the native eardrum. Preliminary bench studies show that the PhonoGraft device not only closed the eardrum perforation; it supported the body’s regeneration of the complex eardrum structure,” said Black, who has joined Desktop Health as the Vice President of Biomaterials and Innovation. “Such graft architectures benefit from the use of 3D printing and permit the eardrum to transmit both low- and high-frequency sound waves.”

The PhonoGraft platform has been validated in preclinical studies in animal models. These studies have shown that as the eardrum heals, native cells and blood vessels grow into the biocompatible PhonoGraft material. Since the graft material is biodegradable, it is expected to be replaced by native tissue over time.

“This technology has potential to ‘intelligently’ support the regeneration of soft tissues in other areas of the body,” said Black.

PhonoGraft technology is in advanced-stage research and development, and currently not available for sale anywhere in the world. Black and her team at Desktop Health intend to conduct additional preclinical studies and pursue FDA review.

About Desktop Health

Based in Newport Beach, California, Desktop Health develops additive manufacturing solutions and advanced materials for personalized patient care. Founded in March 2021 as a healthcare business within Desktop Metal, Inc. (NYSE: DM), the business is vertically integrated to develop, manufacture, and commercialize applications across a range of healthcare specialties. Desktop Health is rapidly focused on developing applications and uncovering opportunities to leverage its bio-printing capabilities within healthcare. For more information on Desktop Health, visit

About Desktop Metal, Inc.

Desktop Metal, Inc., based in Burlington, Massachusetts, is accelerating the transformation of manufacturing with an expansive portfolio of 3D printing solutions, from rapid prototyping to mass production. Founded in 2015 by leaders in advanced manufacturing, metallurgy, and robotics, the company is addressing the unmet challenges of speed, cost, and quality to make additive manufacturing an essential tool for engineers and manufacturers around the world. Desktop Metal was selected as one of the world’s 30 most promising Technology Pioneers by the World Economic Forum and named to MIT Technology Review’s list of 50 Smartest Companies. For more information, visit

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to Desktop Health’s potential and future performance, including its strategic focus, development of new healthcare applications (including PhonoGraft technology), adoption or success of new technologies and applications, and anticipated results. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including, but not limited to: (i) the ability to implement business plans, forecasts, and other expectations and identify and realize additional opportunities; (ii) the regulatory requirements that will apply to Desktop Health technology, products, materials and applications, including by the U.S. Food and Drug Administration and comparable agencies in other countries; (iii) risks associated with Desktop Health products, including product liability or warranty claims; and (iv) other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements” in the Annual Report on Form 10-K/A filed by Desktop Metal, Inc. (“Desktop Metal”) with the U.S. Securities and Exchange Commission (the "SEC") on April 30, 2021, and Desktop Metal’s other filings with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. The forward-looking statements included in this press release speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Desktop Metal assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Desktop Metal does not give any assurance that it will achieve its expectations.


Lynda McKinney

Release Summary

Desktop Health to develop PhonoGraft technology, a 3D printed biofabrication solution that offers a promising pathway for soft tissue regeneration.


Lynda McKinney